HYPAZ: Hypertension Induced by Pazopanib

Phase 2 Terminated 31 enrolled Cambridge University Hospitals NHS Foundation Trust University of Cambridge · collab

NaSingle-groupOpen-labelBasic science

Summary

Pazopanib is a new cancer drug that works by limiting the growth of new blood vessels in tumours. About half of patients who take pazopanib develop high blood pressure (hypertension). This side effect can make patients have to reduce or stop their cancer treatment, and can cause other health problems. The aim of this study is to find out exactly how the drug causes high blood pressure.

Timeline

Start: 2011-04
Primary completion: 2014-09
Completion: 2015-09

Outcome

Outcome not reported

Stopped (Enrollment): “Following DMC review, due to slow recruitment of evaluable patients.”

Publications

Maki-Petaja KM, McGeoch A, Yang LL, Hubsch A, McEniery CM, Meyer PAR, Mir F, Gajendragadkar P, Ramenatte N, Anandappa G, Santos Franco S, Bond SJ, Schonlieb CB, Boink Y, Brune C, Wilkinson IB, Jodrell DI, Cheriyan J. Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial. Hypertension. 2021 May 5;77(5):1591-1599. doi: 10.1161/HYPERTENSIONAHA.120.16454. Epub 2021 Mar 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pazopanib	Small molecule	800 mg	Oral